
Nuvation Bio (NUVB) Stock Forecast & Price Target
Nuvation Bio (NUVB) Analyst Ratings
Bulls say
Nuvation Bio is positioned for success due to their differentiated and novel therapeutic candidates, including taletrectinib, Safusidenib, NUV-1511, and NUV-868. According to their financials, the company generates the majority of its revenue in Japan through out-licensing collaborative agreements, indicating strong partnerships and market potential. With a strong pipeline and positive clinical trial results, Nuvation Bio has the potential for significant growth in the targeted cancer therapy market. Overall, the company has a solid foundation and promising outlook for future success.
Bears say
Nuvation Bio is a biopharmaceutical company with a strong focus on developing novel therapeutic candidates for unmet needs in the oncology space. While their product candidate, taletrectinib, may have potential, the company's heavy reliance on out-licensing agreements for the majority of their revenue and the competitive landscape in the space may present challenges for their commercial success. Additionally, the early nature of their pipeline and potential delays in clinical trials could result in significant risks and delays for their lead programs.
This aggregate rating is based on analysts' research of Nuvation Bio and is not a guaranteed prediction by Public.com or investment advice.
Nuvation Bio (NUVB) Analyst Forecast & Price Prediction
Start investing in Nuvation Bio (NUVB)
Order type
Buy in
Order amount
Est. shares
0 shares